Skip to main content
 

Management Team

We’ve assembled a team of scientists, drug hunters, executives, and visionaries. Our experience is matched only by our passion.

Our team includes industry leaders and seasoned executives all drawn to the common purpose of realizing our mission to deliver on the promise of messenger RNA (mRNA) science to bring new medicines to patients. In addition to extensive experience in the biopharma industry, we share a commitment to the possibilities that mRNA science brings to medicine and a desire to rapidly and effectively advance the science to benefit patients. 

Moderna Executive Committee

Venture Presidents


Stéphane Bancel
Chief Executive Officer

Stéphane joined Moderna in the summer of 2011 when it was a one employee company. He has assembled a world-class team and raised more than $1Billion between equity financing and upfront from licensing collaborations.

He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMerieux has more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion.

Prior to his time at bioMérieux, Stéphane was the managing director of Eli Lilly Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.

He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.

Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for investor relations in France in 2009 and was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. Stéphane serves as a supervisory director of Qiagen N.V., and on the Board of Directors of Syros Pharmaceuticals.

Back to top


Marcello Damiani
Chief Digital Officer

As Chief Digital Officer Marcello brings a wealth of experience from both Tech companies and Life Science companies and a true passion for making Digital a reality. He has 20 years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and in the U.S.

Prior to joining Moderna, Marcello has been instrumental in conceiving and building creative IT solutions to help solve business challenges, first at Motorola and then at bioMerieux. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes. He is known for his ability to transform a company’s Information flow, and ultimately improving the product and the company’s processes through digitization.

Marcello possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and he has just finished an international Executive MBA program through TRIUM, an alliance of three of the world’s top universities: the London School of Economics, New York University Stern Business School and the HEC School of Management in Paris.

Back to top


Stephen W. Harbin
Senior Vice President, Clinical Supply Operations

Steve brings more than 30 years of diverse operational experience in pharmaceuticals and in-vitro diagnostics to his position at Moderna, having served in a variety of senior business and operational leadership roles both in Europe and the U.S. Prior to joining Moderna, he was the corporate vice president of Global Operations at bioMérieux, where he was responsible for more than 3,000 global employees over multiple global functions and manufacturing sites.

In his career Steve has held senior leadership positions driving strategic direction and performance in such areas as, manufacturing, information systems, quality, regulatory affairs, and compliance. He has continually refined and reengineered internal processes driving transformation in response to new business challenges.

Steve has held leadership roles with Eli Lilly and Company, Shionogi Qualicaps (Spain), Elanco Qualicaps (U.K.), and Elanco Animal Health where his work covered many different dimensions from sales and marketing to HR and people development in highly regulated environments, resulting in receiving ‘best practice’ recognition from the FDA.

He graduated in 1979 from Durham College of Agriculture in the UK.

Back to top


Stephen Hoge, M.D.
President

As President of Moderna, Stephen leads all research and development in mRNA technology, including chemistry, biology, formulation, and technical development. In addition Stephen is responsible for New Venture Labs, Moderna’s internal venture incubator and has played a founding role in all of Moderna’s therapeutic area ventures. Having joined Moderna at a very early stage, Stephen has played a wide range of other roles at the company, including leading corporate development & strategy, mRNA science, and preclinical oncology.

Prior to Moderna, Stephen was a partner at McKinsey & Company and a leader in the firm’s healthcare practice. At McKinsey Stephen advised senior management teams of leading biotech and pharmaceutical companies on a wide range of strategic and operational topics. Prior to joining McKinsey, Stephen was a physician in New York. He holds an M.D. with thesis from the University of California, San Francisco and a B.S. in neuroscience from Amherst College.

Currently, Stephen also serves on the board of directors of Axcella, Inc., a clinical stage biotechnology company.

Back to top


Saqib Islam
Chief Business Officer

As Chief Business Officer, Saqib oversees critical aspects of Moderna’s growth, including global strategic planning, corporate development and business development.

Saqib joined Moderna from Alexion, where he served as Executive Vice President, Chief Strategy and Portfolio Officer, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Prior to joining Alexion, Saqib worked for more than 20 years in international business management with a focus on business development, strategic decision-making and planning and capital markets. He has an extensive background in the healthcare banking sector, having held positions of increasing responsibility in the investment banking divisions of Merrill Lynch, Morgan Stanley, and most recently, Credit Suisse Securities. Earlier in his career, Saqib provided strategic analysis and advice to client firms across diverse industry segments for The Boston Consulting Group.

He received a bachelor’s degree from McGill University and a J.D. from Columbia Law School.

Back to top


James R. Kasinger
General Counsel

Jim leads all legal, corporate governance, and intellectual property matters at Moderna.

A highly accomplished attorney with more than 16 years of experience, Jim brings to Moderna an extensive background in corporate law, mergers and acquisitions, securities, and licensing law. Before joining Moderna, Jim was the general counsel at PlumChoice, Inc., a provider of technical support services to Fortune 1000 companies. Prior to PlumChoice, Jim was a partner at the global law firm, Goodwin Procter LLP, where he represented life sciences, technology and other high-growth companies in all stages of their life cycles, from formation, to obtaining seed and growth financings, to initial public offering, merger or sale. Jim started his legal career at Testa, Hurwitz & Thibeault.

Jim holds a JD from Boston College Law School, graduating cum laude, and a B.A. from Wheaton College, graduating magna cum laude.

Back to top


Lorence Kim, M.D.
Chief Financial Officer

Lorence joins Moderna from Goldman Sachs where he was a managing director and co-head of the U.S. biotechnology investment banking effort. He joined Goldman Sachs in 1999 as a summer associate and was named managing director in 2008. As a member of the healthcare investment banking group for nearly 14 years, Lorence’s responsibilities included corporate finance and mergers and acquisitions (M&A) for the pharmaceutical and biotechnology industries, with several billion in equity and equity-linked financings, and more than $55 billion in M&A transactions. Lorence is currently a member of the board of directors of Seres Therapeutics.

Prior to joining Goldman Sachs, Lorence worked in various medical research and consulting positions concurrent with his graduate studies. Lorence graduated from Harvard University, magna cum laude and Phi Beta Kappa with an A.B. in biochemical sciences in 1995. He also earned an MBA in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000 and an M.D. from the University of Pennsylvania’s School of Medicine in 2000.

Back to top


Tal Zaks, M.D., Ph.D.
Chief Medical Officer and President, Caperna

As chief medical officer, Dr. Tal Zaks oversees preclinical development, clinical development and regulatory affairs across Moderna and its ventures. Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization.

Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is associate professor of medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers.

Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.

Back to top


Stephen Kelsey, M.D.
President, Onkaido

Stephen has extensive pharmaceutical industry experience in oncology. After 16 years as an academic clinician, he started his industry career at Sugen, and later was vice president of hematology/oncology at Genentech. While at Genentech, Stephen played a significant role in the development of key products Perjeta®, Kadcyla® and Erivedge®, as well as other molecules in the company’s oncology portfolio. He left Genentech in 2009 to run Geron’s oncology division, where he served for four years as executive vice president, research and development, and chief medical officer helping to develop therapeutics and vaccines to fight cancer.

Most recently Stephen was senior vice president, new projects at the cancer therapies company Medivation. Stephen graduated with a Doctorate of Medicine (M.D.) from the University of Birmingham, UK and is a fellow of both the Royal Colleges of Physicians and Pathologists, UK.

Back to top


Michael Watson, MB ChB, MRCP, AFPM
President, Valera

Dr. Watson is a trained physician in internal medicine and infectious disease, bringing a twenty-year career in vaccine work to his new role with Moderna. Previously, Dr. Watson was Global Head of Vaccination Policy and Advocacy at Sanofi Pasteur. He has also held positions including Head of R&D for Acambis, UK Medical Director of Aventis Pasteur MSD as well as Head of Clinical and Epidemiology for SPMSD in France. His broad experience developing and licensing vaccines for conditions from smallpox, to encephalitis, to influenza and more has involved collaboration with key organizations such as the World Health Organization (WHO), Bill & Melinda Gates Foundation, GAVI (The Vaccine Alliance) and other government and non-governmental organizations. He has served as Chair of the Vaccines Committee and the Pandemic Influenza Preparedness Group of the International Federation of Pharmaceutical Manufacturers Association, (IFPMA) and is a member of the Board of Vaccines Europe and a board member of The Foundation for Innovative New Vaccines, FIND.

Back to top